These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 24726088)

  • 1. Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany.
    Nakamaru Y; Hayashi Y; Sekine M; Kinoshita S; Thompson J; Kawaguchi A; Davies M; Jürgen Heuer H; Yamazaki H; Akimoto K
    Clin Ther; 2014 May; 36(5):760-9. PubMed ID: 24726088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling.
    Nakamaru Y; Emoto C; Shimizu M; Yamazaki H
    Biopharm Drug Dispos; 2015 Apr; 36(3):148-62. PubMed ID: 25450725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment.
    Halabi A; Maatouk H; Siegler KE; Faisst N; Hinrichsen H
    Clin Pharmacol Drug Dev; 2014 Jul; 3(4):290-6. PubMed ID: 27128835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
    Noh YH; Lim HS; Jin SJ; Kim MJ; Kim YH; Sung HR; Choi HY; Bae KS
    Clin Ther; 2012 May; 34(5):1182-94. PubMed ID: 22534255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice.
    Ceriello A; De Nigris V; Iijima H; Matsui T; Gouda M
    Drugs; 2019 May; 79(7):733-750. PubMed ID: 30982160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers.
    Kinoshita S; Kondo K
    Expert Opin Drug Metab Toxicol; 2015 Jan; 11(1):7-14. PubMed ID: 25424014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of Potential Pharmacokinetic Interactions Between Teneligliptin and Metformin in Steady-state Conditions in Healthy Adults.
    Nakamaru Y; Hayashi Y; Davies M; Jürgen Heuer H; Hisanaga N; Akimoto K
    Clin Ther; 2015 Sep; 37(9):2007-18. PubMed ID: 26212570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter prospective observational study of teneligliptin, a selective dipeptidyl peptidase-4 inhibitor, in patients with poorly controlled type 2 diabetes: Focus on glycemic control, hypotensive effect, and safety Chikushi Anti-Diabetes Mellitus Trial-Teneligliptin (CHAT-T).
    Takamiya Y; Okamura K; Shirai K; Okuda T; Kobayashi K; Urata H
    Clin Exp Hypertens; 2020; 42(3):197-204. PubMed ID: 30974980
    [No Abstract]   [Full Text] [Related]  

  • 9. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects.
    Boinpally R; Gad N; Gupta S; Periclou A
    Clin Ther; 2014 Nov; 36(11):1638-49. PubMed ID: 25236915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.
    Friedrich C; Metzmann K; Rose P; Mattheus M; Pinnetti S; Woerle HJ
    Clin Ther; 2013 Jan; 35(1):A33-42. PubMed ID: 23328275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
    Kadowaki T; Kondo K
    Diabetes Obes Metab; 2013 Sep; 15(9):810-8. PubMed ID: 23464664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of teneligliptin in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring.
    Yajima T; Yajima K; Hayashi M; Takahashi H; Yasuda K
    Diabetes Res Clin Pract; 2016 Dec; 122():78-83. PubMed ID: 27810689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans.
    Nakamaru Y; Hayashi Y; Ikegawa R; Kinoshita S; Perez Madera B; Gunput D; Kawaguchi A; Davies M; Mair S; Yamazaki H; Kume T; Suzuki M
    Xenobiotica; 2014 Mar; 44(3):242-53. PubMed ID: 23855261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers.
    Swart PJ; Krauwinkel WJ; Smulders RA; Smith NN
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):33-6. PubMed ID: 16867168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial.
    Eto T; Inoue S; Kadowaki T
    Diabetes Obes Metab; 2012 Nov; 14(11):1040-6. PubMed ID: 22776014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of glimepiride on the pharmacokinetics of teneligliptin in healthy Korean subjects.
    Park JW; Kim KA; Choi YJ; Yoon SH; Park JY
    J Clin Pharm Ther; 2019 Oct; 44(5):720-725. PubMed ID: 31094010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
    Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
    Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
    Frost CE; Byon W; Song Y; Wang J; Schuster AE; Boyd RA; Zhang D; Yu Z; Dias C; Shenker A; LaCreta F
    Br J Clin Pharmacol; 2015 May; 79(5):838-46. PubMed ID: 25377242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ketoconazole on lobeglitazone pharmacokinetics in Korean volunteers.
    Sil Oh E; Ok Kim C; Kim KH; Kim YN; Kim C; Lee JI; Park MS
    Clin Ther; 2014 Jul; 36(7):1064-71. PubMed ID: 25047497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.